Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 6/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 4/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3512541 | 0.87 | RBP4 (0.49) | RBP4NISCHCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3100456 | 0.82 | RBP4 (0.48) | RBP4SCD | |
| SCHEMBL22023666 | 0.81 | RBP4 (0.53) | RBP4NISCHCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL23665229 | 0.78 | RBP4 (0.51) | RBP4CYP1A2CYP2D6CYP2C19HSD17B10 | |
| SCHEMBL22702793 | 0.78 | RBP4 (0.51) | RBP4NISCHCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL14008912 | 0.77 | RBP4 (0.50) | RBP4CYP1A2CYP2D6CYP2C19HSD17B10 | |
| SCHEMBL3121102 | 0.76 | SLC6A4 (0.53) | SCD | |
| SCHEMBL17955457 | 0.74 | SYK (0.52) | RBP4CYP1A2CYP2D6CYP2C19HSD17B10 | |
| SCHEMBL3118290 | 0.74 | SCD (0.53) | CYP2D6SCD | |
| SCHEMBL5365259 | 0.74 | HRH1 (0.57) | RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586571-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RAVER1 | RBP4 1/4885NISCH 3553/4885CYP1A2 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.